Redeye: LIDDS - Another (potential) weapon against cancer

Report this content

Earlier in April LIDDS announced a new project, a Toll-Like Receptor 9 (TLR9) formulated with the NanoZolid platform. Positive preclinical data have been generated so far and LIDDS aims to start Phase I will in 2020. We have included the new project in our valuation which raising our valuation range slightly.

Read more at:

Start following companies at Redeye to recieve the latest research within Technology and Life Science

This is a press release from Redeye - Research Powered Investment Banking.